UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review

Frontiers in oncology, 2023-10, Vol.13

2023

Volltextzugriff (PDF)

The Application of Copper and Silver Nanoparticles in the Protection of Fagus sylvatica Wood against Decomposition by Fomes fomentarius

Forests, 2022-10, Vol.13 (10), p.1724

2022

Volltextzugriff (PDF)

A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience

Frontiers in oncology, 2024-05, Vol.14, p.1395992-1395992

2024

Volltextzugriff (PDF)

Isolated Progression of Multiple Myeloma into the Extramedullary Plasmacytoma of Dura Mater: A Case Report and Review of the Literature

Biomedicines, 2023-04, Vol.11 (4), p.1225

2023

Volltextzugriff (PDF)

Horse phenotyping based on video image analysis of jumping performance for conservation breeding

PeerJ (San Francisco, CA), 2019-08, Vol.7, p.e7450-e7450, Article e7450

2019

Volltextzugriff (PDF)

Na fotografii wszystko jest inaczej. Fotografia jest tym, czym nie jest

Śląskie Studia Polonistyczne, 2022-07, Vol.19 (1), p.1-5

Zarzycka, Ewa

2022

Volltextzugriff (PDF)

Ageing-resembling phenotype of long-term allogeneic hematopoietic cells recipients compared to their donors

Immunity & ageing, 2022-11, Vol.19 (1), p.51-10, Article 51

2022

Volltextzugriff (PDF)

P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE

HemaSphere, 2023-08, Vol.7 (S3), p.e83152da-n/a

2023

Volltextzugriff (PDF)

Pierwszy raz w Drohobyczu

Konteksty, 2019, Vol.324 (1-2), p.508-509

Zarzycka, Ewa

2019

Volltextzugriff (PDF)

First Time in Drohobycz

Konteksty, 2019-01, Vol.1/2 (324/325), p.508

Zarzycka, Ewa

2019

Volltextzugriff (PDF)

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

The New England journal of medicine, 2022-04, Vol.386 (16), p.1519-1531

2022

Volltextzugriff (PDF)

Emicizumab in Management of Hemophilia_A Patients with High Titer FVIII Inhibitor - Real-World Evidence from Poland

Blood, 2022-11, Vol.140 (Supplement 1), p.5621-5622

2022

Volltextzugriff (PDF)

Punkty wyjścia. Z Ewą Zarzycką o sztuce performansu, rysunkach i tekstach w transmedialnym archiwum rozmawiają Marta Baron-Milian i Aleksander Wójtowicz

Śląskie Studia Polonistyczne, 2022-07, Vol.19 (1), p.1-13

2022

Volltextzugriff (PDF)

The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study

Blood, 2021-11, Vol.138 (Supplement 1), p.1208-1208

2021

Volltextzugriff (PDF)

Preclinical and Clinical Evidence for Erythroid-Stimulating Activity of RVU120 CDK8/19 Inhibitor in AML and MDS

Blood, 2023-11, Vol.142 (Supplement 1), p.2800-2800

2023

Volltextzugriff (PDF)

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage

Blood, 2022-11, Vol.140 (Supplement 1), p.6165-6166

2022

Volltextzugriff (PDF)

Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia

Leukemia & lymphoma, 2024-09, Vol.65 (9), p.1292-1302

2024

Volltextzugriff (PDF)

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.5914-5914

2023

Volltextzugriff (PDF)

Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7012-7012

2023

Volltextzugriff (PDF)

Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib + azacitidine or placebo + azacitidine

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e19024-e19024

2022

Volltextzugriff (PDF)

Novel Clinically Useful Inhibitor of Mediator Complex, RVU120, Relives Differentiation Block in MDS/AML

Blood, 2023-11, Vol.142 (Supplement 1), p.3225-3225

2023

Volltextzugriff (PDF)

The Application of Copper and Silver Nanoparticles in the Protection of IFagus sylvatica/I Wood against Decomposition by IFomes fomentarius/I

Forests, 2022-10, Vol.13 (10)

2022

Volltextzugriff (PDF)

AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation

Blood, 2021-11, Vol.138 (Supplement 1), p.697-697

2021

Volltextzugriff (PDF)

RVU120 (SEL120) CDK8/19 Inhibitor - a Drug Candidate for the Treatment of MDS Can Induce Erythroid Differentiation

Blood, 2021-11, Vol.138 (Supplement 1), p.1518-1518

2021

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(77)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review

The Application of Copper and Silver Nanoparticles in the Protection of Fagus sylvatica Wood against Decomposition by Fomes fomentarius

A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience

Isolated Progression of Multiple Myeloma into the Extramedullary Plasmacytoma of Dura Mater: A Case Report and Review of the Literature

Horse phenotyping based on video image analysis of jumping performance for conservation breeding

Na fotografii wszystko jest inaczej. Fotografia jest tym, czym nie jest

Ageing-resembling phenotype of long-term allogeneic hematopoietic cells recipients compared to their donors

P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE

Pierwszy raz w Drohobyczu

First Time in Drohobycz

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

Emicizumab in Management of Hemophilia_A Patients with High Titer FVIII Inhibitor - Real-World Evidence from Poland

Punkty wyjścia. Z Ewą Zarzycką o sztuce performansu, rysunkach i tekstach w transmedialnym archiwum rozmawiają Marta Baron-Milian i Aleksander Wójtowicz

The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study

Preclinical and Clinical Evidence for Erythroid-Stimulating Activity of RVU120 CDK8/19 Inhibitor in AML and MDS

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage

Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study

Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine

Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib + azacitidine or placebo + azacitidine

Novel Clinically Useful Inhibitor of Mediator Complex, RVU120, Relives Differentiation Block in MDS/AML

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

The Application of Copper and Silver Nanoparticles in the Protection of IFagus sylvatica/I Wood against Decomposition by IFomes fomentarius/I

AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation

RVU120 (SEL120) CDK8/19 Inhibitor - a Drug Candidate for the Treatment of MDS Can Induce Erythroid Differentiation

Suchergebnisse filtern